Christoph Petry

Title: Christoph Petry: Innovator in Breast Cancer Prognosis

Introduction

Christoph Petry is a notable inventor based in Cologne, Germany. He has made significant contributions to the field of medical diagnostics, particularly in breast cancer prognosis. With a total of 4 patents to his name, Petry's work focuses on improving patient outcomes through innovative methods.

Latest Patents

One of Christoph Petry's latest patents is a method for breast cancer recurrence prediction under endocrine treatment. This invention relates to methods, kits, and systems designed for the prognosis of disease outcomes in breast cancer patients. The method involves determining RNA expression levels of at least two out of nine specific genes in a tumor sample. These genes include UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP. The expression level values are mathematically combined to yield a score that indicates the prognosis for the patient.

Career Highlights

Throughout his career, Christoph Petry has worked with prominent companies in the healthcare sector. Notable among these are Myriad International GmbH and Siemens Healthcare Diagnostics GmbH. His experience in these organizations has contributed to his expertise in medical diagnostics and innovation.

Collaborations

Christoph Petry has collaborated with several professionals in his field, including Mathias Gehrmann and Guido Hennig. These collaborations have likely enhanced his research and development efforts, leading to impactful inventions.

Conclusion

In summary, Christoph Petry is a distinguished inventor whose work in breast cancer prognosis has the potential to significantly improve patient care. His innovative methods and collaborations reflect his commitment to advancing medical science.